BioSpace

Vir's hepatitis delta combo tamps down virus as Gilead showdown looms

Vir Biotechnology is targeting a mid-2027 regulatory submission for its monthly chronic hepatitis delta regimen, with head-to-head data against Gilead’s Hepcludex expected next quarter.

By BioSpace

1 min read
Vir's hepatitis delta combo tamps down virus as Gilead showdown looms
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights